In the smart money’s world, James E. Flynn’s Deerfield Management just reported a purchase of 2,631,579 shares of Bacterin International Holdings Inc (NYSEMKT:BONE) in a 13G filing with the Securities and Exchange Commission. In total, the holding in Bacterin International Holdings is now worth about $1.5 million at the current price of the stock, and represents 5.04% of the company. This is a new position.
In investment circles, 13Gs indicate intentions of passive hedge fund managers. These members of the “investing elite” aren’t exposed to an equal level of coverage as their activist peers, but passive managers should be analyzed as well. Therefore, it’s very beneficial for retail investors to understand James E. Flynn’s latest investment into Bacterin International Holdings Inc (NYSEMKT:BONE).
While investor’s watch plenty of equity-based metrics, there is one that is especially important: the consensus sentiment of the world’s best money managers.
Quantitative analyses have shown that “monkeys” who follow specific hedge fund activity can outperform Mr. Market by about 18 percentage points per year, over a long-term period. (See the details here).
Focusing in on Bacterin International Holdings Inc (NYSEMKT:BONE), we can see that there were no other hedge funds invested in Bacterin International Holdings Inc (NYSEMKT:BONE) at the end of last quarter. At the end of last year D E Shaw managed by D. E. Shaw held a $17,000 position, which involved almost 14,000 shares, however the hedge fund cut the position in the first three months of 2013.
Just as important, we should mention some other equities in the Deerfield Management’s 13F portfolio, aside from Bacterin International Holdings Inc (NYSEMKT:BONE).
As follows they include, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), Forest Laboratories, Inc. (NYSE:FRX), Merck & Co., Inc. (NYSE:MRK), and are further discussed on the next page: